US 2023/0127277 A1 · MICROBIOME-BASED THERAPEUTICS

Abstract

Provided herein is a method of treating an individual afflicted with an inflammatory bowel disease utilizing Candida abundance as a biomarker of responsiveness. The method comprises determining levels of Candida in a sample from the gastrointestinal tract of an individual, and if the level of Candida is higher than a reference level, identifying the individual as suitable for microbiota transplantation therapy (MTT), and optionally, administering to such an individual the MTT, and in individuals having gastrointestinal tract Candida levels lower than a reference level, increasing the Candida levels prior to prior to administration of MTT.

Claims14

Dependent claims

A method of treating an individual afflicted with an inflammatory bowel disease comprising:

a) in a sample obtained from the individual's gastrointestinal tract, determining the level of Candida sp. to be the same or higher than a reference level;
and administering to the individual, a therapy comprising microbiota transplantation therapy (MTT), or
b) in a sample obtained from the individual's gastrointestinal tract, determining the level of Candida sp. to be lower than a reference level, administering a composition to the individual to increase the level of Candida sp. such that the Candida sp. levels increase to the same or higher level than the reference level, and administering to the individual, a therapy comprising MTT.

Dependencies are inferred from the claim text.

Microbiome-based therapeutics

Life of this patent

Microbiome-based therapeutics

Life of this patent

Abstract

Claims14